A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the market ...